Program
Hizentra
Also written as “IgPro20”, “Human Normal Immunoglobulin for Subcutaneous Administration” and “Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)”.
Its studies are mostly in Primary Immunodeficiency Diseases · Hematologic Neoplasms · Postural Orthostatic Tachycardia Syndrome · Scleroderma, Diffuse · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, led by CSL.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSL | 91 open or running | phase 4since Jan 23, 2017 | Dec 22, 2006 | Sep 27, 2029phase 3 · NCT07648264 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 22, 2006First study: phase 3 study in Primary Immunodeficiency DiseasesFirst studyNCT00419341 · 49 enrolled · United States
- Oct 11, 2007Phase 3 study in Common Variable ImmunodeficiencyNCT00542997 · 51 enrolled · France, Germany, Italy and more
- Jul 21, 2008Phase 3 study in Primary Immunodeficiency DiseasesNCT00719680 · 21 enrolled · United States
- Sep 11, 2008Phase 3 study in Primary Immunodeficiency DiseasesNCT00751621 · 40 enrolled · France, Germany, Poland and more
- Jan 3, 2014Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT02027701 · 82 enrolled · United States, Australia, Canada and more
- Jan 23, 2017Phase 4 study in Primary Immunodeficiency DiseasesNCT03033745 · 49 enrolled · United States, Canada
- Oct 21, 2019Phase 2 study in Scleroderma, DiffuseNCT04137224 · 27 enrolled · Australia, Germany, Italy and more
- Jul 26, 2024Phase 3 study in Post-COVID Postural Orthostatic Tachycardia SyndromeNCT06524739 · 16 enrolled · United States, Canada
- Jun 10, 2026Phase 3 study in Hematologic NeoplasmsNCT07648264 · 63 planned · United States, Belgium, Canada and more
- Oct 14, 2026Primary completion moved from 2029-03-13 to 2029-09-27Date moved laterphase 3 · +7 months · NCT07648264
Ahead
- Sep 27, 2029Primary completion: phase 3 study in Hematologic NeoplasmsNCT07648264
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07648264Hematologic Neoplasms · United States, Belgium, Canada and more | 3 | Recruiting | Sep 27, 2029 | 63 |
| NCT06524739Post-COVID Postural Orthostatic Tachycardia Syndrome · United States, Canada | 3 | Terminated | Jun 20, 2025 | 16 |
| NCT04137224Scleroderma, Diffuse · Australia, Germany, Italy and more | 2 | Completed | May 17, 2022 | 27 |
| NCT03033745Primary Immunodeficiency Diseases · United States, Canada | 4 | Completed | Dec 14, 2018 | 49 |
| NCT02027701Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more | 3 | Completed | Jul 10, 2017 | 82 |
| NCT00751621Primary Immunodeficiency Diseases · France, Germany, Poland and more | 3 | Completed | Dec 2011 | 40 |
| NCT00719680Primary Immunodeficiency Diseases · United States | 3 | Completed | Jun 2010 | 21 |
| NCT00542997Common Variable Immunodeficiency · France, Germany, Italy and more | 3 | Completed | Aug 2009 | 51 |
| NCT00419341Primary Immunodeficiency Diseases · United States | 3 | Completed | Oct 2008 | 49 |
How it is read
Names in the registry
- “IgPro20”, 7 entries
- “Human Normal Immunoglobulin for Subcutaneous Administration”, 1 entry
- “Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)”, 1 entry
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 4 studies
- Hematologic Neoplasms, 1 study
- Postural Orthostatic Tachycardia Syndrome, 1 study
- Scleroderma, Diffuse, 1 study
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.